Percutaneous mitral valve therapy became a reality more than 25 years ago with the first
description of balloon valvuloplasty for rheumatic mitral stenosis. 1 More recently,
percutaneous closure of paravalvular leaks after surgical valve implantation has been
shown to have a potential, but limited, role. 2–4 However, valvular mitral regurgitation (MR)
remains largely the purview of surgery. Recently, the potential for less invasively replicating
these successful surgical procedures without the need for thoracotomy or cardiopulmonary …

Mitral regurgitation (MR) is currently the most frequent valvular heart disease, and the
second most operated valve in Europe. Around 50% of patients presenting severe MR are
denied surgery, despite the adverse prognosis associated with the absence of treatment,
due to comorbidities and/or advanced age. During the previous years, percutaneous
treatment of MR, whether by replacement or, more frequently, by repair, has been
developed, providing an alternative for those patients who are deemed at prohibitive, but …